Bellerophon Therapeutics Stock Price, News & Analysis (NASDAQ:BLPH)

$1.41 -0.06 (-4.08 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$1.41
Today's Range$1.48 - $1.38
52-Week Range$0.43 - $1.98
Volume147,836 shs
Average Volume735,239 shs
Market Capitalization$52.2 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics logoBellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:BLPH
  • CUSIP: N/A
  • Web: www.bellerophon.com
Debt:
  • Current Ratio: 6.15%
  • Quick Ratio: 6.15%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.28 per share
  • Price / Book: 5.04
Profitability:
  • Trailing EPS: ($1.39)
  • Net Income: ($23,810,000.00)
  • Return on Equity: -276.82%
  • Return on Assets: -78.56%
Misc:
  • Employees: 20
  • Outstanding Shares: 55,180,000
 

Frequently Asked Questions for Bellerophon Therapeutics (NASDAQ:BLPH)

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its earnings results on Monday, August, 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. View Bellerophon Therapeutics' Earnings History.

Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2017?

2 analysts have issued twelve-month target prices for Bellerophon Therapeutics' stock. Their predictions range from $4.50 to $5.00. On average, they expect Bellerophon Therapeutics' share price to reach $4.75 in the next twelve months. View Analyst Ratings for Bellerophon Therapeutics.

Who are some of Bellerophon Therapeutics' key competitors?

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the folowing people:

  • Jonathan M. Peacock, Chairman of the Board, President (Age 59)
  • Fabian Tenenbaum, Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director (Age 42)
  • Megan Schoeps, Principal Financial Officer
  • Martin D. Meglasson Ph.D., Chief Scientific Officer, Vice President (Age 65)
  • Reinilde Heyrman M.D., Vice President, Chief Clinical Development Officer and Secretary (Age 54)
  • Martin Dekker, Vice President - Device Engineering (Age 42)
  • Manesh Naidu, Vice President, Chief Business Officer (Age 45)
  • Deborah A Quinn M.D., Vice President - Medical Lead for INOpulse Programs (Age 60)
  • Daniel Tasse, Director (Age 57)
  • Naseem Amin M.D., Independent Director

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Who owns Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PUISSANCE CROSS-BORDER OPPORTUNITIES III LLC (15.10%) and VHCP Management II LLC (7.52%). Company insiders that own Bellerophon Therapeutics stock include Jens Luehring and Jonathan M Peacock. View Institutional Ownership Trends for Bellerophon Therapeutics.

Who bought Bellerophon Therapeutics stock? Who is buying Bellerophon Therapeutics stock?

Bellerophon Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including VHCP Management II LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Jens Luehring and Jonathan M Peacock. View Insider Buying and Selling for Bellerophon Therapeutics.

How do I buy Bellerophon Therapeutics stock?

Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of Bellerophon Therapeutics stock can currently be purchased for approximately $1.41.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $52.2 million. The biotechnology company earns ($23,810,000.00) in net income (profit) each year or ($1.39) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 Liberty Corner Rd Ste 302, WARREN, NJ 07059-6796, United States. The biotechnology company can be reached via phone at +1-908-5744770 or via email at [email protected]


MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Bellerophon Therapeutics (NASDAQ:BLPH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.75 (236.88% upside)

Consensus Price Target History for Bellerophon Therapeutics (NASDAQ:BLPH)

Price Target History for Bellerophon Therapeutics (NASDAQ:BLPH)

Analysts' Ratings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017HC WainwrightReiterated RatingBuy$5.00LowView Rating Details
4/17/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$4.50HighView Rating Details
8/11/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/22/2016FBR & CoReiterated RatingOutperform$11.00N/AView Rating Details
3/22/2016Leerink SwannLower Price TargetOutperform$11.00 -> $9.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Bellerophon Therapeutics (NASDAQ:BLPH)

Earnings by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Earnings History by Quarter for Bellerophon Therapeutics (NASDAQ BLPH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.15)($0.12)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.25)($0.15)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.21)($0.37)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.42)($0.30)ViewN/AView Earnings Details
8/9/2016Q216($0.51)($0.39)ViewN/AView Earnings Details
5/10/2016Q116($0.65)($0.54)ViewN/AView Earnings Details
3/21/2016Q4($1.06)($0.82)ViewListenView Earnings Details
11/12/2015Q315($0.94)($0.86)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.96)($0.90)ViewN/AView Earnings Details
3/31/2015Q4 2014($2.16)($1.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)
2017 EPS Consensus Estimate: ($1.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bellerophon Therapeutics (NASDAQ BLPH)

Insider Ownership Percentage: 60.40%
Institutional Ownership Percentage: 45.86%
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ BLPH)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Jens LuehringDirectorBuy20,000$0.56$11,200.00View SEC Filing  
5/17/2016Jonathan M PeacockCEOBuy5,000$1.37$6,850.00View SEC Filing  
12/16/2015Jonathan M. PeacockCEOBuy20,300$2.75$55,825.00View SEC Filing  
8/19/2015Jonathan M PeacockCEOBuy5,000$5.48$27,400.00View SEC Filing  
5/20/2015Jonathan M PeacockCEOBuy5,560$8.69$48,316.40View SEC Filing  
2/19/2015Daniel TasseDirectorBuy25,000$12.00$300,000.00View SEC Filing  
2/19/2015Jonathan M PeacockCEOBuy20,800$12.00$249,600.00View SEC Filing  
2/19/2015Linde North America, Inc.Major ShareholderBuy358,916$12.00$4,306,992.00View SEC Filing  
2/19/2015Manesh NaiduInsiderBuy1,500$12.00$18,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bellerophon Therapeutics (NASDAQ:BLPH)

Latest Headlines for Bellerophon Therapeutics (NASDAQ BLPH)

Source:
DateHeadline
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 5:32 AM
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial ResultsBellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:28 PM
Bellerophon Therapeutics posts 3Q lossBellerophon Therapeutics posts 3Q loss
finance.yahoo.com - November 7 at 7:28 PM
Bellerophon Therapeutics, Inc. (BLPH) Set to Announce Quarterly Earnings on MondayBellerophon Therapeutics, Inc. (BLPH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filingBRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
www.reuters.com - October 24 at 11:42 PM
Bellerophon Announces $23 Million Private PlacementBellerophon Announces $23 Million Private Placement
finance.yahoo.com - October 2 at 12:59 PM
Reviewing Recro Pharma (REPH) & Bellerophon Therapeutics (BLPH)Reviewing Recro Pharma (REPH) & Bellerophon Therapeutics (BLPH)
www.americanbankingnews.com - September 28 at 6:16 PM
-$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter-$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter
www.americanbankingnews.com - September 13 at 9:30 AM
Bellerophon Therapeutics to Provide Corporate Update at Two Investor ConferencesBellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
finance.yahoo.com - September 7 at 4:49 PM
Bellerophon Therapeutics, Inc. (BLPH) Receives Buy Rating from HC WainwrightBellerophon Therapeutics, Inc. (BLPH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - September 6 at 7:40 AM
Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase ... - StreetInsider.comBellerophon Therapeutics (BLPH) Reports Positive Top Line Phase ... - StreetInsider.com
www.streetinsider.com - September 5 at 11:13 PM
Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase 2 Data of INOpulse for Treatment of PH-COPDBellerophon Therapeutics (BLPH) Reports Positive Top Line Phase 2 Data of INOpulse for Treatment of PH-COPD
www.streetinsider.com - September 5 at 6:11 PM
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary DiseaseBellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
finance.yahoo.com - September 5 at 6:11 PM
Bellerophon shares surge 20% premarket on positive results in trial of COPD treatmentBellerophon shares surge 20% premarket on positive results in trial of COPD treatment
finance.yahoo.com - September 5 at 6:11 PM
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases  Earnings Results, Beats Expectations By $0.03 EPSBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - August 8 at 10:51 AM
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:11 PM
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business UpdateBellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 7 at 5:09 PM
Bellerophon Therapeutics posts 2Q lossBellerophon Therapeutics posts 2Q loss
finance.yahoo.com - August 7 at 5:09 PM
Bellerophon (BLPH) Announces FDA Agreement on Phase 2b Study ... - StreetInsider.comBellerophon (BLPH) Announces FDA Agreement on Phase 2b Study ... - StreetInsider.com
www.streetinsider.com - August 5 at 2:58 AM
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
finance.yahoo.com - August 3 at 6:02 PM
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Scheduled to Post Quarterly Earnings on MondayBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:10 AM
Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon TherapeuticsBiotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics
www.bizjournals.com - May 25 at 10:04 PM
Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM
Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.comBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM
Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulseBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse
www.streetinsider.com - May 23 at 11:51 AM
Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 9:41 AM
BRIEF-Bellerophon to issue 2 mln registered shares of common stockBRIEF-Bellerophon to issue 2 mln registered shares of common stock
www.reuters.com - May 11 at 4:29 PM
Bellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, WarrantsBellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, Warrants
www.streetinsider.com - May 11 at 9:15 AM
Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.comBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.com
www.streetinsider.com - May 2 at 11:49 AM
Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATSBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS
www.streetinsider.com - May 1 at 3:57 PM
Bellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulse® for Pulmonary Arterial Hypertension at ... - StreetInsider.comBellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulse® for Pulmonary Arterial Hypertension at ... - StreetInsider.com
www.streetinsider.com - April 7 at 8:34 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements anBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
biz.yahoo.com - March 16 at 3:17 PM
APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBXAPRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX
www.nasdaq.com - March 14 at 8:42 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportBELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 13 at 11:49 AM
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business UpdateBellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 13 at 11:49 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 13 at 11:49 AM
18 Biggest Mid-Day Gainers For Tuesday - Benzinga18 Biggest Mid-Day Gainers For Tuesday - Benzinga
www.benzinga.com - February 21 at 3:16 PM

Social Media

Financials

Chart

Bellerophon Therapeutics (NASDAQ BLPH) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.